Yearly rate of change of eGFR stratified by mean follow-up SBP during a median follow-up period of 3.2 years
| SBP (mmHg) . | All . | Placebo . | Olmesartan . |
|---|---|---|---|
| ≤130 | −3.27 (−6.90, −1.63), n = 158 | −4.10 (−7.08, −2.33), n = 65 | −2.88*** (−6.65, −1.27), n = 93 |
| 131–140 | −4.53* (−8.08, −2.29), n = 172 | −4.89 (−8.07, −2.59), n = 89 | −4.03 (−8.72, −1.81), n = 83 |
| >140 | −7.13** (−10.90, −3.99), n = 236 | −7.00 (−10.68, −3.84), n = 130 | −7.34 (−11.49, −4.43), n = 106 |
| SBP (mmHg) . | All . | Placebo . | Olmesartan . |
|---|---|---|---|
| ≤130 | −3.27 (−6.90, −1.63), n = 158 | −4.10 (−7.08, −2.33), n = 65 | −2.88*** (−6.65, −1.27), n = 93 |
| 131–140 | −4.53* (−8.08, −2.29), n = 172 | −4.89 (−8.07, −2.59), n = 89 | −4.03 (−8.72, −1.81), n = 83 |
| >140 | −7.13** (−10.90, −3.99), n = 236 | −7.00 (−10.68, −3.84), n = 130 | −7.34 (−11.49, −4.43), n = 106 |
Values are (dL/mg/year) [median (interquartile range)].
*P-value = 0.008 (SBP ≤ 130 versus 131–140 mmHg in all patients).
**P-value < 0.001 (SBP ≤ 130 versus > 140 mmHg in all patients).
***P-value = 0.016 (olmesartan versus placebo in SBP ≤ 130 mmHg).
Yearly rate of change of eGFR stratified by mean follow-up SBP during a median follow-up period of 3.2 years
| SBP (mmHg) . | All . | Placebo . | Olmesartan . |
|---|---|---|---|
| ≤130 | −3.27 (−6.90, −1.63), n = 158 | −4.10 (−7.08, −2.33), n = 65 | −2.88*** (−6.65, −1.27), n = 93 |
| 131–140 | −4.53* (−8.08, −2.29), n = 172 | −4.89 (−8.07, −2.59), n = 89 | −4.03 (−8.72, −1.81), n = 83 |
| >140 | −7.13** (−10.90, −3.99), n = 236 | −7.00 (−10.68, −3.84), n = 130 | −7.34 (−11.49, −4.43), n = 106 |
| SBP (mmHg) . | All . | Placebo . | Olmesartan . |
|---|---|---|---|
| ≤130 | −3.27 (−6.90, −1.63), n = 158 | −4.10 (−7.08, −2.33), n = 65 | −2.88*** (−6.65, −1.27), n = 93 |
| 131–140 | −4.53* (−8.08, −2.29), n = 172 | −4.89 (−8.07, −2.59), n = 89 | −4.03 (−8.72, −1.81), n = 83 |
| >140 | −7.13** (−10.90, −3.99), n = 236 | −7.00 (−10.68, −3.84), n = 130 | −7.34 (−11.49, −4.43), n = 106 |
Values are (dL/mg/year) [median (interquartile range)].
*P-value = 0.008 (SBP ≤ 130 versus 131–140 mmHg in all patients).
**P-value < 0.001 (SBP ≤ 130 versus > 140 mmHg in all patients).
***P-value = 0.016 (olmesartan versus placebo in SBP ≤ 130 mmHg).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
